Temporal changes of angiopoietins and Tie2 expression in rat lungs after monocrotaline-induced pulmonary hypertension

Comparative Medicine

Volumn 59, Issue 4, 2009, Pages 350-356

  Yu, Ji Cho ^a   Jae, Yoon Han ^a   Sang, Gab Lee ^a   Byeong, Tak Jeon ^a   Wan, Sung Choi ^a   Young, Sil Hwang ^a   Gu, Seob Roh ^a   Jong, Deog Lee ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCROTALINE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; HISTOPATHOLOGY; MALE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; BLOTTING, WESTERN; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MONOCROTALINE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TIE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350162245     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Archer S, Rich S. 2000. Primary pulmonary hypertension: a vascular biology and translational research 'work in progress'. Circulation 102:2781-2791.
2. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. 1998. Tie2 receptor ligands, angiopoietin 1 and angiopoietin 2, modulate VEGF-induced postnatal neovascularization. Circ Res 83:233-240. (Pubitemid 28371312)
3. Bouïs D, Kusumanto Y, Meijer C, Mulder NH, Hospers GA. 2006. A review on pro- and antiangiogenic factors as targets of clinical intervention. Pharmacol Res 53:89-103. (Pubitemid 43003475)
4. Brindle NP, Saharinen P, Alitalo K. 2006. Signaling and functions of angiopoietin 1 in vascular protection. Circ Res 98:1014-1023. (Pubitemid 43755222)
5. Cho CH, Kammerer RA, Lee HJ, Steinmetz MO, Ryu YS, Lee SH, Yasunaga K, Kim KT, Kim I, Choi HH, Kim W, Kim SH, Park SK, Lee GM, Koh GY. 2004. COMP-Ang1: a designed angiopoietin 1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci USA 101:5547-5552. (Pubitemid 38481194)
6. Chu D, Sullivan CC, Du L, Cho AJ, Kido M, Wolf PL, Weitzman MD, Jamieson SW, Thistlethwaite PA. 2004. A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiopoietin 1. Ann Thorac Surg 77:449-456. (Pubitemid 38186487)
7. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. 1996. Isolation of angiopoietin 1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169. (Pubitemid 27010100)
8. Davis S, Yancopoulos GD. 1999. The angiopoietins: yin and yang in angiogenesis. Curr Top Microbiol Immunol 237:173-185.
9. Dewachter L, Adnot S, Fadel E, Humbert M, Maitre B, Barlier-Mur AM, Simonneau G, Hamon M, Naeije R, Eddahibi S. 2006. Angiopoietin-Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med 174:1025-1033. (Pubitemid 44684452)
10. Dulak J, Jozkowicz A, Foresti R, Kasza A, Frick M, Huk I, Green CJ, Pachinger O, Weidinger F, Motterlini R. 2002. Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. Antioxid Redox Signal 4:229-240. (Pubitemid 34517174)
11. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML. 1994. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8:1897-1909. (Pubitemid 24273890)
12. Eddahibi S, Humbert M, Sediame S, Chouaid C, Partovian C, Maitre B, Teiger E, Rideau D, Simonneau G, Sitbon O, Adnot S. 2000. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 162:1493-1499.
13. Gaine SP, Rubin LJ. 1998. Primary pulmonary hypertension. Lancet 352:719-725.
14. Gale NW, Yancopoulos GD. 1999. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13:1055-1066.
15. Goto J, Ishikawa K, Kawamura K, Watanabe Y, Matumoto H, Sugawara D, Maruyama Y. 2002. Heme oxygenase 1 reduces murine monocrotaline-induced pulmonary inflammatory responses and resultant right ventricular overload. Antioxid Redox Signal 4:563-568. (Pubitemid 35001439)
16. Hashimoto T, Pittet JF. 2006. Angiopoietin-2: modulator of vascular permeability in acute lung injury? PLoS Med 3:e113.
17. Holash J, Wiegand SJ, Yancopoulos GD. 1999. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356-5362. (Pubitemid 29462372)
18. Igari H, Tatsumi K, Sugito K, Kasahara Y, Saito M, Tani T, Kimura H, Kuriyama T. 1998. Role of EDRF in pulmonary circulation during sustained hypoxia. J Cardiovasc Pharmacol 31:299-305. (Pubitemid 28099172)
19. Kimura H, Esumi H. 2003. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol 50:49-59. (Pubitemid 37034227)
20. Laurén J, Gunji Y, Alitalo K. 1998. Is angiopoietin 2 necessary for the initiation of tumor angiogenesis? Am J Pathol 153:1333-1339.
21. Lobov IB, Brooks PC, Lang RA. 2002. Angiopoietin 2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99:11205-11210.
22. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. 1997. Angiopoietin 2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60.
23. Mata-Greenwood E, Meyrick B, Soifer SJ, Fineman JR, Black SM. 2003. Expression of VEGF and its receptors Flt1 and Flk1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285:L222-L231. (Pubitemid 36736485)
24. Ono S, Voelkel NF. 1991. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol 71:2483-2492.
25. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VP. 2006. Excess circulating angiopoietin 2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 3:e46.
26. Peters KG, Kontos CD, Lin PC, Wong AL, Rao P, Huang L, Dewhirst MW, Sankar S. 2004. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res 59:51-71.
27. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. 1995. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 14:5884-5891.
28. Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR. 1997. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol 272:H806-H813. (Pubitemid 27142635)
29. Risau W. 1997. Mechanisms of angiogenesis. Nature 386:671-674.
30. Schnürch H, Risau W. 1993. Expression of tie 2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119:957-968. (Pubitemid 23337434)
31. Schroeder RA, Ewing CA, Sitzmann JV, Kuo PC. 2000. Pulmonary expression of iNOS and HO1 protein is upregulated in a rat model of prehepatic portal hypertension. Dig Dis Sci 45:2405-2410.
32. Sullivan CC, Du L, Chu D, Cho AJ, Kido M, Wolf PL, Jamieson SW, Thistlethwaite PA. 2003. Induction of pulmonary hypertension by an angiopoietin 1-TIE2-serotonin pathway. Proc Natl Acad Sci USA 100:12331-12336. (Pubitemid 37271560)
33. Thistlethwaite PA, Lee SH, Du LL, Wolf PL, Sullivan C, Pradhan S, Deutsch R, Jamieson SW. 2001. Human angiopoietin gene expression is a marker for severity of pulmonary hypertension in patients undergoing pulmonary thromboendarterectomy. J Thorac Cardiovasc Surg 122:65-73. (Pubitemid 33733690)
34. Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G. 2002. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor 2, and angiopoietin 2. J Clin Invest 109:777-785. (Pubitemid 34263154)
35. Visconti RP, Richardson CD, Sato TN. 2002. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA 99:8219-8224. (Pubitemid 34651033)
36. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. 1997. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81:567-574. (Pubitemid 27432744)
37. Xue C, Rengasamy A, Le Cras TD, Koberna PA, Dailey GC, Johns RA. 1994. Distribution of NOS in normoxic vs hypoxic rat lung: upregulation of NOS by chronic hypoxia. Am J Physiol 267:L667-L678.
38. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
39. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD, Grumet M. 1999. In situ expression of angiopoietins in astrocytomas identifies angiopoietin 2 as an early marker of tumor angiogenesis. Exp Neurol 159:391-400.
40. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ. 2003. Protective role of angiopoietin 1 in experimental pulmonary hypertension. Circ Res 92:984-991. (Pubitemid 36588497)